Emerging evidence suggests that alternative splicing dependent tumours, like mutant p53 PDAC and both MYC and SF3B1 (splicing factor) mutation-driven cancers, are more vulnerable to further perturbation in splicing [33,34,95,102,103,104,105,106,107]. The gene discussed is MYC; the disease is neoplasm.